FOLH1 and prostate carcinoma: Recent reports on the superiority of prostate-specific membrane antigen (PSMA)–targeted PET imaging over the conventional modalities for prostate cancer at initial staging and recurrence have increased interest in exploring its utility for RCC (7–9).